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Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic
kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels
and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with
paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels
with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is
that  of a mediator in mineral and bone homeostasis. However, recent studies have suggested
that  the beneﬁts of treatment with paricalcitol go beyond PTH reduction and, for instance,
it  has a positive effect on cardiovascular disease and survival. The objective of this study
is  to review the most signiﬁcant studies on the so-called pleiotropic effects of paricalcitol
treatment in patients with CKD.
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Efectos  pleiotrópicos  del  paricalcitol,  más  allá  del  metabolismo
óseo-mineral
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Trasplante
r  e  s  u  m  e  n
El hiperparatiroidismo secundario (HPTS) es una complicación habitual en pacientes con
enfermedad renal crónica que se caracteriza por unos niveles elevados de hormona
paratiroidea (PTH) y una serie de anomalías en el metabolismo mineral-óseo. En pacientes
con  HPTS, el tratamiento con paricalcitol, un activador selectivo de los receptores de la vita-
mina  D, ha demostrado reducir los niveles de PTH con mínimas variaciones del calcio y del
fósforo séricos. El efecto clásico de paricalcitol es el de mediador en la homeostasis min-
eral  y ósea. Sin embargo, estudios recientes han indicado que los beneﬁcios del tratamiento
con paricalcitol van más allá de la reducción de PTH, por ejemplo, ocasionando efectos
positivos en la enfermedad cardiovascular y en la supervivencia. El objetivo del presente
trabajo es revisar los estudios más signiﬁcativos sobre los llamados efectos pleiotrópicos
del  tratamiento con paricalcitol en pacientes con ERC.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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he classic physiological role of the vitamin D hormonal sys-
em is in the essential regulation of bone mineral metabolism.
,25-dihydroxyvitamin D3 binds with a high afﬁnity to vita-
in  D receptors (VDR) and regulates serum levels of calcium
Ca) and phosphorus (P) by increasing their absorption in
he intestine, increasing calcium reabsorption in the renal
ubules, and suppressing secretion of parathyroid hormone
PTH), which in turn is a key regulator of mineral metabolism.1
he decrease in 1,25-dihydroxyvitamin D3 levels is attributed
o the increased production of FGF23 induced by the accu-
ulation of phosphate, which stimulates FGF23 production,
ven without an evident increase in serum P concentra-
ion. Therefore, vitamin D deﬁciency plays a central role in
he development of secondary hyperparathyroidism (SHPT),
 common early complication in patients with chronic kid-
ey disease (CKD)2–4 that progresses as glomerular ﬁltration
ate decreases.4 SHPT is characterised by high PTH levels and
he presence of bone and mineral abnormalities.1,2 SHPT and
bnormal mineral metabolism lead to clinical consequences
t 2 levels: in the musculoskeletal system and in the cardio-
ascular system. The consequences in the musculoskeletal
ystem are due to increased bone remodelling, the most com-
on  condition being osteitis ﬁbrosa. The consequences on the
ascular system are related to the increased risk of vascular
alciﬁcation.2
The usual treatment for SHPT involves dietary phospho-
us restriction and drugs such as phosphate binders, VDR
ctivators (selective and non-selective), and/or calcimimetics
uch as cinacalcet.2,3
The ﬁrst commercial VDR activator (VDRA) was calcitriol.2
alcitriol is an important drug in the treatment of SHPT
n patients with CKD. However, due to its potent effects
n intestinal Ca and P absorption, this molecule frequently
nduces hypercalcaemia, hyperphosphatemia, and renal cal-
uli formation, and increases the likelihood of calciﬁcation.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
In 1998, paricalcitol was approved for the treatment of
SHPT.5 This third-generation vitamin D analogue emerged in
view of the need for treatments that could inhibit high PTH
concentrations in patients with SHPT, with a minimal effect
on serum concentrations of Ca, P, and the calcium-phosphorus
product (Ca × P), without renal toxicity.4 Recently, paricalci-
tol has been reclassiﬁed by the World Health Organisation to
H05BX (other antiparathyroid agents) rather than A11CC (vita-
min  D and analogues).
The beneﬁcial effect of paricalcitol in reducing PTH levels
in patients with CKD is widely established.4 Its therapeutic
efﬁcacy is due to the tissue selectivity of its mechanism of
action.4 Paricalcitol is considered a selective VDR activator.
The term “selective” refers to the differential binding of the
ligand to the VDR. The synthesis of selective vitamin D recep-
tor activators (sVDRA) such as paricalcitol and maxacalcitol
came about because of the clinical need to broaden the thera-
peutic window of the classic vitamin D forms and to try to
reduce the risk of hypercalcaemia and hyperphosphatemia
associated with the non-selective derivatives calcitriol and
alfacalcidol. Selective VDRAs allow more  efﬁcient inhibition
of PTH synthesis and secretion, with a lesser effect on intesti-
nal absorption of calcium and phosphorus.6 The selectivity
of paricalcitol is explained at a biochemical level by the C-
terminal of the vitamin D receptor, which is the region that
binds speciﬁcally to the ligand.6
Although current clinical practice guidelines for CKD limit
the use of VDRAs to the treatment of SHPT,7 the VDR has been
identiﬁed in more  than 30 different human tissues (Table 1).8
This suggests the different actions that vitamin D may have,
in addition to those related to bone and mineral homeostasis,
giving what are known as the “non-classical” effects of vitamin
D. Such effects include an anti-inﬂammatory immunomodu-
latory effect on cardiomyocyte remodelling,9 a renal protective
effect, and to a lesser degree, an effect on the progression of
vascular remodelling, particularly in some derivatives.
The wide dissemination of VDRs in human tissues explains
some potential effects in terms of improved cardiovascular
12  n e f r o l o g i a. 2 0 1 
Table 1 – Tissue distribution of vitamin D receptors.
System Tissue
Endocrine Parathyroid, pancreatic B cells, thyroid C
cells
Cardiovascular Arterial smooth muscle cells, cardiac
myocytes
Musculoskeletal Osteoblasts, chondrocytes, striated muscle
Gastrointestinal Oesophagus, stomach, intestine
Hepatic Liver parenchymal cells
Renal Tubules, juxtaglomerular apparatus (renin),
podocytes
Reproductive Testicles, ovaries, uterus
Immune T cells, B cells, bone marrow, thymus
Respiratory Alveolar cells of the lung
Epidermis Keratinocytes, hair follicles
1Central nervous
system
Neurons
structure and function, reducing the risk of cardiovascular
disease and mortality, particularly in patients with CKD.6
Paricalcitol  and  survival  in  haemodialysis
patients
SHPT affects to, at least, half of all patients with end-stage
renal disease on dialysis10 and is associated with different
diseases and comorbidities, such as increased risk of frac-
ture, vascular complications, and infections. Many  of these
comorbidities may lead to hospital admission. Dobrez et al.
observed that patients treated with paricalcitol had a lower
risk of all-cause hospitalisation (–14%; P < .0001), fewer hospi-
talisations per year (–0.642; P < .001), and fewer hospital days
per year (–6.84; P < .001) than patients treated with calcitriol.10
Furthermore, several epidemiological studies have shown
the signiﬁcant systemic effect of VDR activation on survival,
in patients with SHPT on haemodialysis.5,11 The results of the
ﬁrst study demonstrated that treatment with paricalcitol led
to a mortality rate that was 16% lower than with the VDRA
calcitriol (95% CI).5 In that retrospective cohort study, the dif-
ference in survival was signiﬁcant at 12 months of treatment
and increased over time (P < .001) (Figure 1a).5 Within that
study, there was one subgroup of patients that changed from
treatment with calcitriol to treatment with paricalcitol. At 2
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years, that subgroup of patients had a higher survival rate than
the subgroup who changed from treatment with paricalcitol
to treatment with calcitriol (73% vs 64%, P < .04) (Figure 1b).5
The survival advantage for patients treated with paricalcitol
over those treated with calcitriol appears to be independent
of baseline serum levels of calcium, phosphorus, and PTH.5
In a second retrospective study, patients who  received i.v.
vitamin D (calcitriol or paricalcitol) showed a survival rate 20%
higher than those who did not receive vitamin D (HR, 0.80; 95%
CI).11 Survival at 2 years was 75.6% in the group of patients who
received vitamin D, vs 58.7% in the group of patients who  did
not receive vitamin D (P < .001).11 The survival advantage for
patients treated with i.v. vitamin D over with those not treated
with vitamin D also appears to be independent of baseline
calcium, phosphate, and PTH levels (Figure 2).11
Another published study by Kalantar-Zadeh et al. also asso-
ciated treatment with paricalcitol with improved survival, in
a cohort of patients on maintenance haemodialysis.12 The
authors observed that treatment with the vitamin D recep-
tor activator paricalcitol at any dose was associated with
improved survival compared with those patients who  were not
treated with paricalcitol.12,13 Subsequently, Lee et al. compiled
the results of the study by Kalantar-Zadeh et al. and similarly
demonstrated that the administration of paricalcitol at any
dose was associated with improved survival in subgroups of
patients on maintenance haemodialysis (Figure 3).13
Possible  mechanisms  to  explain  the  survival
beneﬁt  associated  with  systemic  activation  of
vitamin  D  receptors
Vascular protection: paricalcitol in vascular calciﬁcation,
atherosclerosis, and cardiac structure and function.
Patients with stage 5 CKD on dialysis have a high rate
of mortality due to cardiovascular complications.14–17 Several
studies have shown that vitamin D deﬁcit and activation of
the vitamin D receptor are associated with vascular calciﬁ-
cation and dysfunction and cardiovascular mortality, in both
the general population and in patients with CKD. Calciﬁca-
tion of vascular tissue is common in patients with CKD14,16
and has haemodynamic consequences, such as loss or arterial
elasticity, increased pulse wave velocity, development of left
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Sentricular hypertrophy, reduced coronary artery perfusion,
yocardial ischaemia, and heart failure.17 This calciﬁcation
ccurs at 2 distinct levels in the vessel: in the intimal layer,
ere it is associated with atherosclerosis, and in the medial
ayer, where it is associated with arteriosclerosis due to factors
uch as age, diabetes, and end-stage renal failure.14,17
The exact mechanisms responsible for the development
nd progression of vascular calciﬁcation in patients with
KD are not completely known.16 For many  years, it has
een proposed that vascular calciﬁcation is the result of a
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ource: Adapted from Lee et al.,13 2007.passive process, due to high phosphate levels and a high
Ca × P product.17 However, recent studies have shown a rela-
tionship between vascular calciﬁcation and osteogenesis,17
indicating that vascular calciﬁcation is an actively-regulated
process.17,18
Calcitriol and other vitamin D analogues are used for
the treatment of SHPT, but there is some disagreement
regarding whether or not these VDR activators directly
accelerate the vascular calciﬁcation process.17 For example,
in vitro and in vivo studies have demonstrated that cal-
citriol induces calciﬁcation at high doses. However, other
VDRAs, such as paricalcitol, are less likely to cause hyper-
calcaemia and hyperphosphatemia or to induce vascular
calciﬁcation.16
VDRAs can have differential effects on vascular calci-
ﬁcation, and these effects are independent of the Ca × P
product,14,16 serum levels of Ca and P,14 and PTH.16 Unlike
paricalcitol, calcitriol15,16 and doxercalciferol14,16 appear to
increase aortic calcium content in studies with uraemic
post-nephrectomy rats. Even more  importantly, calcitriol and
doxercalciferol appear to increase the expression of Cbfa-1
(RunX-2), a transcription factor that initiates the active mech-
anisms of vascular calciﬁcation.16
It is known that vascular smooth muscle cells (VSMC)
have VDRs and contain the enzyme 25-hydroxyvitamin D3 1-
hydroxylase, indicating that vitamin D and its analogues play
an important role in the function and physiology of this cell
type.17 In a study by Cardús et al., high doses of calcitriol, but
not of paricalcitol, increased calciﬁcation in VSMCs of post-
nephrectomy rats.18 The same study showed that treatment
 2 0 1 14  n e f r o l o g i a.
with hypercalcaemiant doses of calcitriol increased pulse
pressure (the difference between systolic arterial pressure and
diastolic arterial pressure), probably due to the extensive arte-
rial calciﬁcation observed. In contrast, in rats treated with
paricalcitol, no increase was observed in aortic calciﬁcation
or pulse pressure.18
Noonan et al. quantiﬁed the functional consequences of
vascular calciﬁcation and observed that paricalcitol had no
effects on pulse wave  velocity, whereas high doses of doxer-
calciferol increased pulse wave  velocity in post-nephrectomy
rats at 6 weeks of study.
While the activation of VDRs can slow vascular calci-
ﬁcation in induced uraemia, recent data also support the
role of VDR activation in the prevention or slowing of
atherosclerosis.8 VDRAs have shown a beneﬁcial effect on
thrombosis, inﬂammation, and vasodilatation, risk factors
associated with endothelial function and the atherosclerotic
process.19 According to a study performed in primary cultures
of human aortic smooth muscle cells, VDRs may play a role in
atherosclerosis by regulating plasminogen activator inhibitor-
1, thrombospondin-1, and thrombomodulin. Thus, VDRs could
contribute to the therapeutic beneﬁt that vitamin D analogues
have in reducing morbidity and mortality risk in patients with
stage 5 CKD.20
A subsequent study assessed the protector effect of par-
icalcitol, an angiotensin-converting enzyme inhibitor (ACEI)
(enalapril), and a combination of both, on oxidative dam-
age in atherosclerotic mice aortas.21 In the study, paricalcitol
alone, enalapril alone, and a combination of paricalcitol
plus enalapril all prevented atherosclerotic plaque forma-
tion in ApoE21-deﬁcient mice and showed a protector effect
against cardiac oxidative stress in uraemia.22 This pro-
tection against the inﬂammation and oxidative damage
of atherosclerosis was greater with the combined ther-
apy (enalapril + paricalcitol) than with monotherapy.21 In the
results of the study, it was observed that both paricalcitol
and enalapril as monotherapies, as well as the combination
of the two, reduced the concentration of the enzyme aortic
malondialdehyde (MDA)  and increased levels of the enzyme
glutathione peroxidase (GSH-Px).21 Both the reduction of MDA
levels and the increase in GSH-Px levels are indicative of the
protector effect of paricalcitol, enalapril, and the combination
of both, in this model of atherosclerotic mice.21 In addition,
paricalcitol also appears to improve endothelial function in
uraemic rats in a dose-dependent manner and independently
of PTH levels and blood pressure.19
In addition, it is thought that paricalcitol is associated with
a lower cardiovascular morbidity, possibly due to modiﬁcation
of cardiac structure and function.23,24 The PRIMO study dealt
with determining the effects of paricalcitol on left ventricular
mass over a period of 48 weeks in patients with CKD and left
ventricular hypertrophy.23,24 During the study period, parical-
citol did not reduce left ventricular mass or improve certain
Doppler measurements of diastolic function, but it did appear
to be associated with fewer hospitalisations for cardiovascu-
lar causes.23 In a post hoc analysis of the PRIMO study, there
was a signiﬁcant reduction in left ventricular volume index in
the group of patients treated with paricalcitol compared with
those in the placebo group (P = .002).246;3  6(1):10–18
Renal  protection:  reduction  of  proteinuria  and  renal
ﬁbrosis
Several studies have demonstrated the renoprotective effect
of vitamin D analogues in experimental animal models with
glomerular disease.25
Diabetic nephropathy, which is characterised by glomeru-
lar lesions, inﬂammatory inﬁltration, tubular atrophy, and
interstitial ﬁbrosis,26 is one of the most complex renal diseases
and is often associated with cardiovascular complications.
Tubulointerstitial damage or ﬁbrosis in CKD leads to end-stage
renal failure.27 In a mouse model with interstitial obstructive
nephropathy due to unilateral ureteric ligation,27 parical-
citol reduced interstitial inﬂammation and the production
and accumulation of interstitial matrix components (colla-
gen and ﬁbronectin). In this model, paricalcitol also inhibited
the transition of epithelial cells to mesenchymal cells, a
process that is partly responsible for renal ﬁbrosis.27 In addi-
tion, paricalcitol restored the number of VDRs in obstructive
nephropathy.27 Paricalcitol also blocked in vitro and in vivo
expression of the Snail gene, Snail being a transcription factor
that plays a crucial role in initiating epithelial to mesenchy-
mal  transition. These results indicate that the beneﬁcial effect
of paricalcitol is associated with its capacity to preserve
the tubular epithelial phenotype by suppressing transition.27
Likewise, paricalcitol has a beneﬁcial inhibitory effect on
renal inﬂammation thanks to signalling-sequestration of
nuclear transcription factors such as nuclear factor kappa B
(NF-KB).26
The urinary protein/albumin ratio is an important marker
of renal and cardiovascular disease28,29 that is associated
with CKD progression.1 Increased urinary protein reﬂects a
higher degree of glomerular disease or underlying renal tubu-
lar dysfunction,1 and plays a direct role in progression of renal
and cardiovascular disease.1,28,29
The renin–angiotensin–aldosterone system (RAAS) has
been identiﬁed as an important mediator of progressive
renal damage in diabetic nephropathy. The drugs that affect
the RAAS, such as ACEIs and angiotensin receptor block-
ers (ARBs), can delay cardiovascular and renal morbidity and
mortality.30 However, residual proteinuria may be high in
patients that receive these treatments1; therefore, different
treatment strategies are needed to reduce that residual risk.1
Recent studies have shown that the selective activation of
VDRs could be of relevance in the reducing proteinuria in
patients with CKD.29
In a post hoc analysis of a randomised trial that assessed
the efﬁcacy of oral paricalcitol in reducing PTH in patients
with CKD,3,4 a reduction in proteinuria was observed in
more than 50% of the patients treated with paricalcitol.
This reduction was independent of concomitant treatment
with RAAS inhibitors (P = .004).28 In another randomised
double-blind study, paricalcitol signiﬁcantly reduced protein
excretion measured by the urinary protein-creatinine ratio at
baseline and at the end of the study in 2 groups of patients:
one treated with paricalcitol and the other with placebo.29In one short study, 24 patients were randomly assigned to
receive placebo, 1 g of paricalcitol, or 2 g of paricalcitol.
Following evaluation, a reduction in proteinuria was observed
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The VITAL study showed that treatment for 24 weeks with
 g of paricalcitol reduced residual albuminuria in patients
ith type 2 diabetes mellitus and kidney disease that were
eing treated with stable doses of ACEIs or ARBs.30 The change
n the urinary albumin-creatinine ratio (UACR) from baseline
evel to the end of treatment was greater in the groups of
atients treated with paricalcitol (1 or 2 g) than in the placebo
roup (P = .071). Fig. 4 shows how the differences in UACR
ppeared to have a dose-response relationship with the use of
aricalcitol, indicating that paricalcitol could be an important
djuvant treatment in the reduction of residual albuminuria.30
A recently-published meta-analysis of 9 studies (n = 832)
y Cheng et al. conﬁrmed the beneﬁcial effect of paricalci-
ol in reducing proteinuria (P = .001) without increased risk of
dverse effects.32
aricalcitol  as  an  immunomodulatory  and
nti-inﬂammatory  agent
everal epidemiological studies have associated vitamin
 deﬁciency with an increased susceptibility to immune-
ediated diseases, including chronic infections and auto-
mmune diseases.33 Systemic inﬂammatory processes are
ommon in patients with CKD and constitute a marker of
oor prognosis.1 It is also known that immune cells express
itamin D activator enzymes, allowing local conversion of
nactive vitamin D to its active form 1,25(OH)(2)D(3).33 These
ata indicate that vitamin D plays a role in maintaining
mmune homeostasis.33 Several studies have evaluated the
mmunomodulatory effect of paricalcitol and other VDRAs in
his area.25,30,33
Paricalcitol and calcitriol have been demonstrated to
educe differentiation of immature dendritic cells from
onocytes and their activation capacity.25 The preven-
ion of dendritic cell maturation may play an important
ole in the prevention of autoimmune diseases, including
therosclerosis.25 The immunomodulatory action of vitaminD also occurs through regulation of the activity of differ-
ent types of immune cells, such as macrophages, dendritic
cells, and T cells,33,34 and regulation of expression of the pro-
inﬂammatory cytokines RANTES and TNF-.34
Tan et al. also observed a beneﬁcial effect from paricalcitol
on the inhibition of renal inﬂammation, due to seques-
tration of NF-KB signalling.34 Another short, randomised
double-blind study in patients with CKD showed a signiﬁ-
cant reduction of serum concentration of C-reactive protein
(CRP), measured using a high-sensitivity method.31 Likewise,
paricalcitol was associated with inﬂammation modulation
in patients on haemodialysis by a reduction in inﬂam-
matory biomarkers such as CRP and TNF- and improved
IL-6/IL-10 and TNF-/IL-10 ratios.35 These anti-inﬂammatory
effects of paricalcitol were independent of iPTH concentration
(Figure 5).35
In another recently published study by Sánchez-Nin˜o et al.,
an anti-inﬂammatory effect was observed for both paricalci-
tol and calcitriol in an experimental model using rats with
streptomycin-induced diabetes. Calcitriol and paricalcitol
reduced the expression of the anti-inﬂammatory mediatorsFig. 5 – Changes in the ratio of pro-/anti-inﬂammatory
cytokines.
Source:  Adapted from Navarro-González et al., 2011.
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Importance  of  paricalcitol  in  transplant  patients
A normal-functioning renal transplant corrects the endocrine
and metabolic imbalances secondary to renal function
deterioration.37,38 However, after renal transplant, persistent
elevation of PTH is observed in a considerable percentage
of patients. Whilst it usually returns to normal slowly in
patients with normal graft function, in patients with mild or
moderate deterioration of renal function it can persist indef-
initely. The persistence of high PTH is a risk factor for loss
of bone mass and increased risk of fracture. Reduced bone
mineral density has also been associated with an increased
risk of atherosclerosis.39 Therefore, better control of PTH may
improve both aspects.
Furthermore, several studies have shown that at one
year post-transplant, proteinuria is present in up to 45% of
patients; in two thirds of these patients, the level is below
500 mg/day.40,41 Proteinuria is one of the factors that signiﬁ-
cantly predisposes to reduced renal graft survival.42
As there is a certain degree of similarity between chronic
graft disease and chronic kidney disease, is can be assumed,
logically, that antiproteinuric therapeutic approaches could be
beneﬁcial in renal transplant patients.43,44 As has been seen
throughout this review, in patients with CKD, paricalcitol has
been shown to be capable of reducing proteinuria in both
patients with SHPT and those with normal PTH levels.
Experience with paricalcitol in renal transplant patients is
limited; however, in the few studies that have been published,
paricalcitol appears to have been effective in improving con-
trol of PTH and proteinuria in this group of patients.
In a retrospective study that included 58 renal transplant
patients with secondary hyperparathyroidism, treatment with
paricalcitol signiﬁcantly reduced serum iPTH levels and pro-
teinuria (35% decrease relative to baseline levels). Renal
function remained stable during treatment with paricalcitol,
with a signiﬁcant difference compared with the deteriora-
tion observed in the 2 years prior to treatment.45 In another,
prospective study in a population of 46 transplant patients
that assessed urinary peptidome, treatment with 1 g/day of
paricalcitol for 3 months effectively reduced PTH levels and
notably modiﬁed the urinary peptide proﬁle.37 In another
study, published only as an abstract, that compared the
use of different vitamin D analogues in patients with renal
transplant, treatment with paricalcitol was associated with a
greater reduction in proteinuria.46
Toxicity from calcineurin inhibitors is one of the most
signiﬁcant causes of chronic graft disease. At an experimen-
tal level, it has been observed that paricalcitol attenuates
cyclosporine-induced nephropathy, suppressing interstitial
inﬂammation and ﬁbrosis and epithelial tubule cell ﬁbrosis.47
This could be, therefore, an additional beneﬁcial effect
of paricalcitol in renal transplant patients on calcineurin
inhibitors.
ConclusionsParicalcitol, a third-generation VDRA, provides effective
control of SHPT with minimal hypercalcaemic and hyper-
phosphatemic effects.4 Its therapeutic efﬁcacy is due to the6;3  6(1):10–18
tissue selectivity of its mechanism of action, as it does not up-
regulate the intestinal vitamin D receptor and is less active
than calcitriol at a bone level.4
Recent studies have indicated that the beneﬁts of parical-
citol go beyond the reduction of PTH and bone and mineral
homeostatic control. This review shows that the pleiotropic
effects of paricalcitol on cardiovascular structure and func-
tion, proteinuria, and immune function, amongst others,1,8,9
may explain the increased survival rate observed in patients
with CKD treated with paricalcitol.5
Although more  experience is needed, use of paricalcitol in
renal transplant patients appears to be a safe and promising
option for improving control of high PHT levels and protein-
uria.
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